Opus Genetics, Inc. - Common Stock (NQ:IRD)

4.650 UNCHANGED

Delayed Quote Updated: 4:00 PM EDT, Oct 9, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

Headline News about Opus Genetics, Inc. - Common Stock

Unusual volume stocks are being observed in Thursday's session. ↗

September 10, 2026

Via Chartmill

Wednesday's session: top gainers and losers ↗

September 09, 2026

Via Chartmill

12 Health Care Stocks Moving In Wednesday's Intraday Session ↗

September 09, 2026

Gainers Opus Genetics (NASDAQ:IRD) shares increased by 31.7% to $5.71 during Wednesday's regular session. The company's market cap stands at $361.0 million. bioAffinity Technologies (NASDAQ:BIAF)...

Via Benzinga

Top stock movements in today's session. ↗

September 09, 2026

Via Chartmill

Gapping stocks in Wednesday's session ↗

September 09, 2026

Via Chartmill

Opus Genetics Touts Retinal Gene Therapy Pipeline, September BEST1 Data Catalyst ↗

May 25, 2026

Opus Genetics (NASDAQ:IRD) is advancing a portfolio of gene therapies for inherited retinal diseases, with two programs already in the clinic and three more expected to enter clinical testing within...

Via MarketBeat

Wondering what's happening in today's after-hours session? ↗

December 31, 2025

Via Chartmill

12 Health Care Stocks Moving In Friday's After-Market Session ↗

November 07, 2025

Via Benzinga

12 Health Care Stocks Moving In Thursday's After-Market Session ↗

November 06, 2025

Via Benzinga

This Celestica Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Thursday ↗

October 16, 2025

Via Benzinga

Viatris Hits Snag In Eye Drug Study—Phase 3 Plans Under Review ↗

July 18, 2025

Viatris' Phase 3 trial for pimecrolimus 0.3% in blepharitis did not meet its primary goal, prompting the company to reassess its development strategy.

Via Benzinga

Viatris Eye Drops Data Shows Promise For Blurred Near Vision ↗

June 26, 2025

Viatris and Opus Genetics report MR-141 met efficacy and safety goals in Phase 3 VEGA-3 trial for presbyopia, with strong patient-reported benefits.

Via Benzinga

12 Health Care Stocks Moving In Friday's Pre-Market Session ↗

June 20, 2025

Via Benzinga

Unusual volume stocks in Tuesday's session ↗

June 03, 2025

Unusual volume stocks are being observed in Tuesday's session.

Via Chartmill

Discover the top movers in Friday's pre-market session. ↗

March 21, 2025

As the US market prepares to open on Friday, let's get an early glimpse into the pre-market session and identify the stocks leading the pack in terms of gains and losses.

Via Chartmill

12 Health Care Stocks Moving In Tuesday's Intraday Session ↗

March 18, 2025

Via Benzinga

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.